What Ignis Treats: Main Uses and Benefits

Ignis is commonly used across two distinct therapeutic domains that are generally relevant for easing symptoms related to physiological functional stress. These applications may help address symptom clusters that create noticeable physiological strain and interfere with daily functioning.

The medication is used for managing the symptomatic conditions of erectile dysfunction (ED) and Pulmonary Arterial Hypertension (PAH). Ignis is commonly applied when supportive symptom management is appropriate in situations where additional management of discomfort is required, particularly in scenarios where symptoms are episodic or chronic.

Ignis is relevant for easing symptoms that interfere with daily functioning, such as the inability to sustain an erection or systemic symptoms like shortness of breath and fatigue associated with high lung pressure. This therapeutic assistance may support patients during difficult episodes by easing distress and assists with maintaining functional stability.

---

Quick Fact: Relief for Functional Strain Ignis is used to help manage conditions where symptoms arise from functional difficulty linked to organ-specific functional stress, contributing to improved day-to-day comfort.

Regulatory References

1. NIH MedlinePlus Drug Information

The eligibility for Ignis (Sildenafil) is strictly governed by regulatory documentation and is defined by specific health conditions and patient populations.

Contraindicated Populations (Must Not Use)

Ignis is absolutely contraindicated in patients taking organic nitrates or nitrites in any form, or soluble guanylate cyclase (sGC) stimulators (e.g., riociguat), due to the risk of severe hypotension. Use is also prohibited for individuals with a known hypersensitivity to sildenafil, severe hepatic impairment, hypotension (blood pressure < 90/50 mmHg), or a recent history of stroke or myocardial infarction.

Age-Related and Conditional Eligibility

Population Group	Eligibility Status	Conditions for Use
Adult Men	Eligible	Indicated for erectile dysfunction.
Pediatric (Under 18)	Not Indicated	Not approved for the erectile dysfunction indication.
Older Adults (mathbfgeq 65 years)	Restricted Use	Requires special consideration due to reduced drug clearance.
Severe Renal/Hepatic Impairment	Restricted Use	Requires special consideration due to reduced drug clearance.
Pregnant/Lactating Women	Conditional Use	Use is subject to risk assessment, particularly for the pulmonary arterial hypertension indication.

Use is not recommended for patients with Pulmonary Veno-Occlusive Disease (PVOD) or patients with conditions that predispose them to priapism (e.g., sickle cell disease).

The official regulatory profile for Ignis (Sildenafil) identifies specific drug, food, and substance interactions based on documented pharmacokinetic and pharmacodynamic mechanisms.

Interaction-Related Restrictions

Co-administration is strictly contraindicated with all forms of Organic Nitrates and Nitric Oxide Donors, as well as Guanylate Cyclase (GC) Stimulators (e.g., Riociguat). This prohibition is due to the officially documented risk of a severe, potentially fatal, additive hypotensive effect. Concomitant use with other Phosphodiesterase type 5 (PDE5) inhibitors is not recommended.

Pharmacokinetic and Exposure Changes

Ignis is cleared predominantly by the hepatic enzyme CYP3A4. Inhibitors of this enzyme, such as Ritonavir or Ketoconazole, reduce the drug’s clearance, leading to significantly increased plasma exposure (AUC/Cmax). Conversely, CYP3A4 inducers (e.g., Bosentan) may decrease exposure. A time separation requirement is imposed when co-administering with Ritonavir, limiting the maximum single dose within a 48-hour period.

Pharmacodynamic and Substance Effects

• Co-administration with alpha-blockers or other anti-hypertensives may result in an additive hypotensive effect. Caution is advised to mitigate the risk of symptomatic hypotension.
• Consumption with a high-fat meal reduces the rate of absorption, causing a delay in the time to peak plasma concentration (Tmax) and a slight reduction in overall peak concentration (Cmax).
• In certain populations, such as those with severe hepatic impairment or elderly patients, higher plasma levels have been observed, which may alter the overall interaction sensitivity.

Selective Inhibition of the PDE5 Enzyme

Ignis (Sildenafil) operates by modulating the body's natural signaling system that regulates vascular tone. The primary mechanism involves selective competitive inhibition of the Phosphodiesterase type 5 (PDE5) enzyme, which is responsible for breaking down the crucial intracellular messenger molecule, cyclic Guanosine Monophosphate (cGMP). By blocking PDE5, the drug prevents cGMP from being rapidly deactivated, causing its concentration to accumulate within specific vascular smooth muscle cells.

---

Potentiation of the Nitric Oxide-cGMP Pathway

This accumulation of cGMP directly potentiates (amplifies) the effects of the natural Nitric Oxide (NO)-cGMP signaling pathway, which is initiated by physiological stimuli. The sustained, higher levels of cGMP activate downstream effectors, resulting in the relaxation of vascular smooth muscle. This key physiological consequence reduces local vascular resistance and results in an increase in localized blood flow to the target tissue.

---

Prerequisite of Endogenous NO Release

The mechanism is strictly dependent on the activation of the endogenous pathway. It requires the prior local release of Nitric Oxide (NO) to start the cGMP cascade, establishing a critical functional constraint for the drug's activity.

How to Use Ignis

The administration of Ignis (Sildenafil) is structured into two distinct official protocols based on the condition being treated, adhering strictly to guidelines for dosage and timing.

Administration Route and Dosing Regimens

The primary route is oral via tablets or suspension for both indications. An intravenous (IV) bolus injection is an approved route but is strictly limited to patients with Pulmonary Arterial Hypertension (PAH) who are temporarily unable to tolerate the oral form.

For Erectile Dysfunction (ED), the medication is used as needed, not continuously. The usual starting dose is 50 mg, which can be adjusted downwards to 25 mg or upwards to a maximum of 100 mg. Administration should occur approximately 30 minutes to four hours prior to activity, and the dose must not exceed once per day.

For PAH, the drug is taken on a scheduled regimen of three times a day (TID). The typical dose is 20 mg TID, with doses spaced between four and eight hours apart, and a maximum approved dose of 80 mg TID in some regions. The 10 mg IV dose is considered pharmacologically equivalent to the 20 mg oral dose.

Special Administration Rules

Ignis may be taken with or without food; however, a high-fat meal can delay the absorption and onset of action. For the ED indication, a starting dose of 25 mg should be considered for older adults (aged 65 and above) and patients with severe renal or hepatic impairment. The oral suspension requires reconstitution and accurate measurement using the designated dosing syringe before administration.

Research Evidence / Overview of Studies for Ignis

Evidence for Use in Erectile Dysfunction (ED)

The foundational research for Ignis is composed of short-term, placebo-controlled clinical trials. These studies were applied in research contexts involving adult men experiencing Erectile Dysfunction (ED) from various underlying causes. Researchers examined the use of Ignis compared to a non-active treatment (placebo) over defined time intervals, typically ranging from a few weeks to a few months.

Research reports patterns observed in the studies related to the measured outcomes of achieving and maintaining an erection. Research is limited regarding direct comparative evidence between Ignis and other similar medicines in its class. Furthermore, there is limited information available for long-term outcomes; the durability of observations over many years is not fully established.

Evidence for Use in Pulmonary Arterial Hypertension (PAH)

Research for Ignis, in the context of PAH, involved Randomized Controlled Trials (RCTs). These studies evaluated outcomes related to systemic or functional imbalance by measuring changes in physical ability and internal physiological parameters. Studies monitored patient exercise capacity, such as the 6-Minute Walk Distance (6MWD), and described patterns related to changes in pulmonary vascular resistance.

Longer-term extension studies monitored outcomes like the time until clinical worsening was observed. While Ignis was studied for two specific indications, comparative evidence is lacking for many direct, head-to-head comparisons against other available therapies.

Research in Special Patient Populations

Research has explored the use of Ignis in populations beyond the general adult population. For ED, studies included men with co-existing conditions, such as diabetes mellitus and hypertension. For the PAH indication, specific clinical trials were conducted in the pediatric population (children aged 1 to 17 years). Regulators noted specific patterns of concern regarding chronic use and safety for long-term use in children based on certain observations from one of the multi-year extension trials.

Key Studies & References

1. Effects of Different Doses of Sildenafil for Pulmonary Arterial Hypertension (Dose-ranging study post-approval)

Common questions about Ignis (FAQ)

Q: How long does Ignis stay in my system/how long do the effects last?

A: According to official product information, the active substance sildenafil, and its major active metabolite, has a terminal half-life of about 4 hours based on studies in healthy volunteers. The maximum concentration of the medication in the blood is typically reached within 30 minutes to two hours after it is taken by mouth.

---

Q: What are the common side effects of Ignis?

A: Official product information from regulatory sources indicates that the most commonly reported side effects observed in clinical trials were headache, flushing, and dyspepsia (indigestion or upset stomach). Other frequently reported effects include abnormal vision (such as a color tinge), nasal congestion, back pain, and dizziness.

---

Q: What happens if I miss a scheduled dose of Ignis for PAH?

A: For patients using this medication for Pulmonary Arterial Hypertension (PAH), official guidance indicates that a missed dose should be taken as soon as it is remembered, followed by a return to the regular dosing schedule. Official information stresses that a double dose should not be taken to compensate for the missed dose.

---

Q: Are there generic versions of Ignis available?

A: Ignis is a trade name for the active substance Sildenafil citrate. Regulatory authorities have approved and granted marketing authorization for generic medicines that contain Sildenafil. These generic versions are considered bioequivalent to the original branded medicine, which means they are expected to work the same way in the body.

---

Q: What are the specific signs of liver problems I should watch for?

A: Documented cases of liver injury are rare, but official safety warnings advise patients to be aware of certain signs. These symptoms can include fatigue, nausea, dark urine, or yellowing of the skin or eyes (jaundice). If any signs of liver injury are observed, immediate medical consultation is required, as stated in the product warnings.

---

Q: Can women use Ignis for any condition?

A: The medication, when used to treat Pulmonary Arterial Hypertension (PAH) under the trade name Revatio, is authorized for adult patients, including women, who meet the eligibility criteria for the condition. Official regulatory information confirms the medication is not indicated for the treatment of Erectile Dysfunction in women.

---

Q: What should I do if I think I took too much Ignis?

A: In the event a patient suspects they have taken too much of this medication, product information advises seeking immediate emergency medical attention or contacting a Poison Control center. Clinical studies involving very high single doses resulted in adverse reactions similar to those seen at lower doses, but with an increase in their incidence and severity.

Storage and Disposal Conditions for Ignis

Ignis (Sildenafil) must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C.

The medicine must be kept in its original container and the container must remain tightly closed to protect the tablets from moisture and light. It is a mandatory safety instruction to keep Ignis and all medicines out of the sight and reach of children.

Disposal Requirements

Unused or expired Ignis must be disposed of according to local requirements. The official guidance recommends utilizing a drug take-back program when available. If a take-back program is not accessible, the product should be prepared for household trash disposal following authorized methods, and must not be disposed of via wastewater or drains.